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Mounds View, Minnesota, and kValley Health System, Ridgewood, New Jersey.BACKGROUND Cardiac resynchronization therapy (CRT) requires a
high percentage of ventricular pacing (%Vp) to maximize its clinical
benefits. Atrial fibrillation (AF) has been shown to reduce %Vp in
CRT due to competition with irregular intrinsic atrioventricular
(AV) conduction. We report the results of a prospective randomized
crossover trial evaluating the amount of effective CRT delivered dur-
ing AF with a novel algorithm (eCRTAF).
OBJECTIVE The purpose of this study was to determine whether
eCRTAF increases the amount of effective CRT delivered during AF
compared to a currently available rate regularization algorithm.
METHODS Patients previously implanted with a cardiac resynchro-
nization therapy-defibrillator and with a history of AF and intact AV
conduction received up to 4 weeks of control (Conducted AF
Response) and up to 4 weeks of eCRTAF in a randomized sequence.
The percent effective CRT (%eCRT) pacing, which excludes beats
without left ventricular capture, %Vp, and mean heart rate (HR)
were recorded during AF and sinus rhythm.The CRTee study was funded by Medtronic plc. ClinicalTrials.gov
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1547-5271/© 2017 The Authors. Published by Elsevier Inc. on behalf of Heart Rh
This is an open access article under the CC BY-NC-ND license (http://creativecom
licenses/by-nc-nd/4.0/).RESULTS The eCRTAF algorithm resulted in a significantly higher %
eCRT during AF than control (87.8% 6 7.8% vs 80.8% 6 14.3%;
P,.001) and %Vp during AF than control (90.0%6 5.9% vs 83.2%6
11.9%; P ,.001), with a small but statistically significant increase in
mean HR of 2.5 bpm (79.56 9.7 bpm vs 77.06 9.9 bpm; P,.001).
CONCLUSION In a cohort of CRT patients with a history of AF,
eCRTAF significantly increased %eCRT pacing and %Vp during AF
with a small increase in mean HR. This algorithm may represent a
novel noninvasive method of significantly increasing effective CRT
delivery during AF, potentially improving CRT response.
KEYWORDS Atrial fibrillation; Biventricular pacing; Cardiac re-
synchronization therapy; Effective pacing; Heart failure
(Heart Rhythm 2018;15:369–375) © 2017 The Authors. Published
by Elsevier Inc. on behalf of Heart Rhythm Society. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cardiac resynchronization therapy (CRT) provides significant
benefits in both morbidity and mortality for heart failure (HF)
patients with reduced ejection fraction and a wide QRS.
Achieving these benefits requires a high percentage of ventric-
ular pacing (%Vp). Retrospective analyses have shown that
even small reductions in CRT pacing are associated with
increased morbidity and mortality.1–3 The reduced efficacyof CRT in some patients with atrial fibrillation (AF) has
been attributed to reduced %Vp due to competition with
irregular intrinsic atrioventricular (AV) conduction, which
can lead to pacing-refractorymyocardium. SomeCRTdevices
use rate regularization algorithms during AF (Conducted AF
Response [CAFR]—Medtronic plc; Ventricular Rate Regula-
tion—Boston Scientific) to modulate pacing rate in an attempt
to reduce the loss of%Vp.4However, the performance of these
algorithmshas not been evaluated in aCRTpatient population.
Accurately determining the amount of CRT being deliv-
ered is made even more difficult because standard device pac-
ing counters cannot distinguish left ventricular (LV) pacing
that is delivered to refractory myocardium (i.e., pseudofu-
sion) from LV pacing that succeeds in depolarizing a signif-
icant portion of the LV (i.e., effective CRT pacing). A new
device-based diagnostic, percent effective CRT (%eCRT)
pacing, quantifies actual CRT delivery using beat-to-beat
ythm Society.
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Figure 1 Flow diagram for the study design. AF 5 atrial fibrillation;
CRT 5 cardiac resynchronization therapy.
370 Heart Rhythm, Vol 15, No 3, March 2018analysis of the paced morphology of the unipolar LV electro-
gram. This diagnostic has been validated against the 12-lead
ECG and has been shown to accurately identify 98.2% of
effectively paced beats.5 When applied to a general CRT pa-
tient population in an observational study (N5 57), the diag-
nostic demonstrated that %Vp overestimated %eCRT pacing
by an average of 7.3% 6 22.2% (P ,.05).6
A novel algorithm has been developed that increases the
amount of effectiveCRTdelivered duringAF (eCRTAF).Using
the %eCRT diagnostic, it monitors beat-to-beat LV capture dur-
ingAFandadjustspacing rate tomaximize%eCRTpacingwhile
minimizing any increase in pacing rate.We report the results of a
prospective randomized crossover trial evaluating the amount of
effective CRT delivered during AF with this new algorithm.Methods
The CRTee download study was a prospective randomized
crossover study enrolling CRT patients with a history of
AF. The study compared a commercially available algorithm
(CAFR) with a novel algorithm (EffectivCRT during AF
[eCRTAF]). The primary endpoint was %eCRT during AF,
with additional endpoints of %Vp during AF and mean heart
rate (HR) during AF. Cardiovascular adverse events (AEs)
also were recorded. An additional acute comparison of no al-
gorithm, CAFR, and eCRTAF was performed in those sub-
jects who were in AF at the time of the office visit.
Subjects
Participants provided fully informed written consent and
were enrolled by site personnel trained in the study and desig-
nated for this task.The study recruited patients with a previously implanted
Medtronic Viva or Brava cardiac resynchronization
therapy-defibrillator (CRT-D) device. The inclusion/exclu-
sion criteria included the following:
Inclusion
 A Viva or Brava device had been implanted for at least 30
days
 AFburden: At least 6 dayswith at least 4 hours ofAF during
a 4-week period occurring within 90 days or clinical diag-
nosis of permanent AF (when no device datawere available)
 Demonstrated history of being able to complete the LV
Capture Management nightly test
 Less than or equal to 97% Vp during AF.
Exclusion
 AV nodal ablation
 Complete or third-degree heart block
 Myocardial infarction within 30 days
Study design
The study outline is shown in Figure 1. Baseline data were
collected at the phase 1 visit, and the eCRTAF algorithm
and the ambulatory diagnostics of %eCRT pacing were
downloaded to the CRT-D devices using a modified model
2090 programmer. The patient was then randomized 1:1 to
either control (i.e., CAFR algorithm) or eCRTAF first.
Randomization allocations were stratified by site and gener-
ated by the study sponsor. Each week, the subject completed
a remote transmission. The phase 2 visit was scheduled when
the programmed algorithm had been active for at least 2 hours
or 4 weeks had passed, whichever came first. At the phase 2
visit, the patient was crossed over to the alternative algo-
rithm, and the transmission process was repeated. After col-
lecting at least 2 hours of data under the programmed
algorithm (or 4 weeks had passed), the phase 3 visit was
scheduled. The phase 3 visit could have been the exit visit,
or, if desired, the eCRTAF algorithm could have remained
on for up to 4 months postrandomization. This additional
time of algorithm operation outside of the randomized phases
was not included in the primary analysis of the trial.
CAFR (control)
CAFR is an algorithm that was designed to regularize the ven-
tricular response to AF. Medtronic CRT devices have this al-
gorithm programmed on by default because it tends to
increase pacing. When the device is not trying to track the
atrium, the algorithm measures the variability of the intervals
between ventricular events (both paced and sensed) and
dynamically adjusts the pacing rate. The algorithm is not
able to distinguish between paces that were delivered but did
not capture and those that did capture. This was used as control
because it is active by default in the CRT-D devices used in the
study.
EffectivCRT during AF (eCRTAF)
The eCRTAF algorithm is designed to maximize percent LV
capture while minimizing the increase in pacing rate. It
AF episode detected
Ini?a?on: 30 beats, each beat evaluated 
Pacing Rate Adjusted
VS VP VP VP VS VP VP VP VP VP VP VP VS VP VP VP VP VP VP VP VP VS VP VP VP VP VP VP VP VS VP VP VP
Maintenance: 30 seconds
Evalua?on:     10 beats, each beat evaluated 
Pacing Rate Adjusted
S?ll 
in 
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Algorithm OFF
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Figure 2 Flow diagram for the EffectivCRT during AF (eCRTAF) algorithm. AF 5 atrial fibrillation.
Plummer et al New Algorithm Increases CRT During AF 371operates only during mode switch or VVIR pacing mode. It
consists of 3 phases: initiation, maintenance, and evaluation
(Figure 2).
During the initiation phase, the algorithm evaluates
eCRT on 30 consecutive beats, adjusting the pacing rate af-
ter each beat to achieve the minimum pacing rate that max-
imizes eCRT pacing as quickly as possible. Ventricular
sensed events or ineffective LV pacing results in small in-
creases in the pacing rate, whereas effectively paced ven-
tricular events result in small decreases in pacing rate.
After the initiation phase, the algorithm enters a mainte-
nance phase during which the pacing rate is maintained
for 30 seconds. After the maintenance phase, while
continuing at the current pacing rate the algorithm moves
to a brief evaluation phase of 10 beats. Each beat is assessed
for effectiveness, and, at the end of the evaluation phase, a
pacing rate is determined based on the number of ventricu-
lar sensed events, and effective and ineffective paced beats.
After the evaluation phase, the algorithm returns to the
maintenance phase and then continues to cycle between
evaluation and maintenance phases until the end of the
AF episode.%eCRT5
effective C
effective CRT paced beats 1 ineffectiveThe eCRTAF algorithm includes 4 safety features to limit
increases inHR. First, there is a programmablemaximumpac-
ing rate. Second, during a daily test, the device confirms that it
can deliver effective CRT pacing with a short sensed or paced
atrioventricular interval or an accelerated rate during a non-
tracking mode, in both biventricular and LV-only modes. If
effective CRT pacing cannot be achieved, the algorithm is
disabled for the day. Third, the algorithm is suspended if the
pacing rate reaches the programmedmaximum rate and the de-
vice still detects ineffective capture in 4 of 5 paced beats.
Finally, the proportion of sensed or ineffective CRT paced
beats required to increase pacing rate increases as the pacing
rate rises. This makes the algorithm progressively less aggres-
sive as the pacing rate increases.
Data collection
During each phase of the study, eCRT pacing was evaluated
continuously during AF (or while the device was in VVIR
mode). If the subject was in normal sinus rhythm, eCRT pac-
ing was evaluated every hour for 100 consecutive beats at 25
minutes past the hour. The accumulated %eCRT pacing was
defined as follows:RT paced beats
CRT paced beats 1 ventricular sensed events
372 Heart Rhythm, Vol 15, No 3, March 2018Ventricular sense response beats were treated as sensed
beats. Separate metrics of %eCRT pacing and %Vp were
maintained for time spent in AF and sinus rhythm. Device
counters and diagnostics were downloaded at each clinic visit.
%Vp and mean HR since last interrogation were recorded.
During the phase 1 office visits, if the subject was in AF,
%eCRT pacing and pacing rate were assessed over 3-minute
periods with no algorithm, with CAFR, and with eCRTAF.
The order of CAFR and eCRTAF was randomized, and
each algorithm had its own control period with no algorithm.Study oversight
The studywas approved by the local institutional reviewboard
or the Medical Ethics Committee and the national regulatory
body for each country in which the study was conducted.
AEs were adjudicated by the Adverse Event Adjudication
Committee. The committee consisted of 3 physicians not
involved in the study. All AEs and deaths were reviewed by
the committee and evaluated for relatedness to the algorithm
aswell as category, such as cardiovascular or noncardiovascular.Table 1 Subject demographics at the time of enrollment (N5 54)Data and statistical analysis
The primary objective of the study was to demonstrate that,
during AF, %eCRT with eCRTAF applied was noninferior
to when CAFR was applied. If this objective was met, the su-
periority objective could be evaluated to determine whether,
during AF, %eCRT with eCRTAF applied was greater than
when CAFR was applied. The lower confidence limit for
the difference between treatment and control had to exceed
the noninferiority margin of 22% in order to meet the pri-
mary objective. To meet the superiority objective, the lower
confidence limit for the difference had to exceed 0%. For
both objectives, the 1-side type I error rate was controlledFigure 3 Cohort distribution of study participants.at the 0.025 level. Sample size was driven by the more strin-
gent superiority objective; with 80% power, assumed true
difference of 6% and standard deviation of 15%, and a
planned interim analysis at 60% of accrual, a total sample
size of 54 subjects with paired data was required.
For continuous variables, mean 6 SD are reported. For
categorical variables, frequency and percentage are reported.
The %Vp, %eCRT pacing, and mean HR during AF were
compared between eCRTAF and control (CAFR) using
paired t tests. P ,.05 was considered significant. Each sub-
ject needed to have at least 2 hours of data in each phase of
the study (eCRTAF and control) to be considered a complete
dataset included in the final analysis.
A multivariate regression analysis was performed to iden-
tify factors that might be associated with greater increases in
%eCRT pacing. The factors that were explored included age,
gender, HF etiology, New York Heart Association functional
class, AF classification, AF medications, programmed lower
pacing rate, and programmed upper tracking rate at baseline,
HR during AF under control, and % pacing during AF under
control. The final model was selected using a backward elim-
ination method keeping all factors with P ,.2 in the model.
All analyses were conducted using SAS software version 9.4
(SAS Institute, Cary, NC).Results
Seventy-one subjects were enrolled in the study from 22 cen-
ters in the United States, Europe, and the Middle East be-
tween October 2014 and January 2016. Follow-up was
completed in January 2016. Of the 66 subjects randomized,Male 50 (92.6)
Age (years) 71.0 6 10.5
Left ventricular ejection fraction (%) 28.8 6 8.1
Intrinsic QRS duration (ms) 157.3 6 36.4
Heart rate (bpm) 76.1 6 10.6
New York Heart Association functional class
I 6 (11.1)
II 22 (40.7)
III 16 (29.6)
Not available 10 (18.5)
Left bundle branch block 26 (48.1)
Coronary artery disease 28 (51.9)
Ischemic cardiomyopathy 21 (38.9)
AV conduction status 54 (100)
First-degree block 3 (5.6)
Second-degree block 0 (0)
Third-degree block 0 (0)
Atrial fibrillation 54 (100)
Permanent 28 (51.9)
Persistent 21 (38.9)
Paroxysmal 5 (9.3)
Rate/rhythm control drugs 54(100)
Class III antiarrhythmic drug 7 (13.0)
Beta-blocker 51 (94.4)
Calcium channel blocker 4 (7.4)
Cardiac glycoside 27 (50.0)
Values are given as n (%) or mean 6 SD.
50
60
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Mean Heart Rate (bpm)
p < 0.001
79.577.0
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Figure 4 Effect of treatment (EffectivCRT during AF [eCRTAF]) on percent ventricular pacing (% V pacing) (left), % effective CRT pacing (middle), and
mean heart rate (right). Light blue bars indicate control (Conducted AF Response [CAFR]). Dark blue bars indicate eCRTAF. Error bars indicate standard de-
viation. AF 5 atrial fibrillation; CRT 5 cardiac resynchronization therapy.
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hours in each phase) available for analysis (Figure 3).
The characteristics at the time of enrollment of the 54
subjects included in the analysis are given in Table 1.
Twenty-eight (52%) were in permanent AF, defined as a clin-
ical diagnosis of permanent AF and continuous AF in the 7
most recent days of device trend data for subjects with an atrial
lead (n 5 20) or as a clinical diagnosis of permanent AF for
subjects with no atrial lead (n 5 8). Subjects with at least 24
hours of AF for at least 7 consecutive days but who did not
meet the criteria for permanent AF were categorized as persis-
tent. Subjects with paroxysmal AFwere those who had AF but
not for 7 consecutive days at any time. All subjects were taking
at least one of the following categories of drugs for rate or
rhythm control: beta-blockers, Ca21 channel blockers, cardiac
glycosides, or class III antiarrhythmic drugs.Primary results
During AF, the eCRTAF algorithm resulted in a significantly
higher %eCRT than control (87.8% 6 7.8 % vs 80.8% 6
14.3%; P,.001), meeting both the primary objective of non-
inferiority and the secondary objective of superiority. %Vp
was also significantly higher during AF (90.0% 6 5.9% vs
83.2% 6 11.9%; P ,.001), and there was a small but statis-
tically significant increase in mean HR of 2.5 bpm (79.5 6
9.7 bpm vs 77.0 6 9.9 bpm; P ,.001) (Figure 4). As ex-
pected, there were negative correlations between mean HR
and %eCRT and between mean HR and %VP (Pearson cor-
relation coefficient 20.75 and 20.68, respectively). In addi-
tion, 5 subjects went from ,90% eCRT during control to
.90% eCRT during eCRTAF. Five more subjects improved
from ,95% eCRT during control to .95% eCRT during
eCRTAF. Of the 54 patients, 42 showed an increase in %
eCRT with eCRTAF. Of the remaining 12 patients, 4 had a
decrease in eCRT of ,1%, another 6 had a decrease 3%,
and the remaining 2 had reductions of 3.3% and 7.6%.Subgroup analyses
Subjects with lower %Vp during the control (CAFR) phase
showed a greater increase in %eCRT with eCRTAF thanthose who were already achieving a high %Vp (Figure 5).
Subjects who received , 80%Vp during control showed
the greatest increase in both %Vp (14.9% 6 5.5%; P
,.001) and %eCRT (15.76 6.9%; P,.001) with eCRTAF
compared to control. There was also an increase in mean HR
of 2 bpm from 82 to 84 bpm (P,.01) in these subjects from
control to eCRTAF. Subjects with %Vp between 80% and
95% during control showed a 2.2 6 4.2 point increase in
%eCRT with eCRTAF (P ,.05). There was no significant
difference in %eCRT or HR with eCRTAF in subjects with
.95% Vp during control.
In a multivariate analysis, lower %Vp during control
continued to result in a greater impact of the algorithm
(P ,.001). This is consistent with the univariate analysis
shown in Figure 5. In addition, a higher HR during control
significantly reduced the increase in %eCRT with the algo-
rithm (P ,.05). Finally, having paroxysmal AF (as opposed
to persistent or permanent AF) significantly increased the
likelihood of a greater increase in %eCRT with the algorithm
(P ,.01). None of the other factors considered had a signif-
icant effect.
Acute testing data were available from 42 subjects
comparing no algorithm to CAFR and from 39 subjects
comparing no algorithm to eCRTAF. CAFR increased %
eCRT pacing from 66% 6 35% (no algorithm) to 79% 6
20% (P ,.001). eCRTAF increased %eCRT pacing from
67% 6 37% (no algorithm) to 87% 6 17% eCRT pacing
(P ,.001). Although these tests were brief, the acute results
for CAFR (79% 6 21%) and eCRTAF (87% 6 16%) are
consistent with the primary results of the study (81% 6
14% for CAFR/control and 88% 6 8% for eCRTAF).Safety
The algorithm performed as expected and did not result in
any unexpected device issues. There were 7 cardiovascular-
related AEs during eCRTAF and 3 during CAFR (P 5
.37). AEs included shortness of breath (n 5 4), hypotension
(n 5 2), implantable cardioverter–defibrillator shock for
rapidly conducted AF (n 5 1), fatigue (n 5 1), and ventric-
ular arrhythmia (n 5 2). None of the AEs that occurred
50
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Figure 5 Results subgrouped by percent ventricular pacing (%Vp) under
control (top), % effective CRT (middle), and mean heart rate (bottom).
Light blue bars indicate control (Conducted AF Response [CAFR]). Dark
blue bars indicate EffectivCRT During AF (eCRTAF). Error bars indicate
standard deviation.
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algorithm or any increase in pacing rate.Discussion
On average, the eCRTAF algorithm resulted in a 7% absolute
increase in eCRT pacing and %Vp during AF while
increasing the mean HR by 2.5 bpm. The algorithm had an
even greater effect in subjects with lower %Vp during AF
while in the control arm.
Two algorithms currently are available in CRT devices to
increase pacing during AF, but both were designed for and
tested in a bradycardia pacemaker population. Ventricular
Rate Regulation (VRR, Boston Scientific) has not been eval-
uated in a CRT patient population; however, in a pacemakerpopulation with AF, the algorithm was shown to increase %
Vp from 38% to 58%.7 The rate regularization algorithm in
Medtronic devices (CAFR) was used as the control in this
study. On average, CAFR achieved 80.8% 6 14.3% eCRT
pacing and 83.2% 6 11.9% Vp during AF. Limited data
are available regarding delivery of CRT during AF in CRT
patients without such an algorithm. Based on the limited
acute data from this study, the eCRTAF algorithm may pro-
duce large increases in %Vp and %eCRT when compared to
patients without a rate regularization algorithm.
Although there are data on the optimal %Vp for CRT dur-
ing AF, there are no similar data for %eCRT during AF.
Because each beat classified as effective CRT is a V pace
beat by definition, loss of %eCRT will be at least as clinically
important as loss of %Vp. However, establishing a %eCRT
threshold for optimal CRTwill require additional clinical data.
Several retrospective analyses demonstrated that small de-
creases in %Vp (1%–3%) are associated with a significant in-
crease in mortality.1–3 Koplan et al2 showed that a decrease of
as little as 1%–4% in ventricular pacing was associated with a
significant negative impact on survival free fromHF hospital-
ization and all-cause mortality. In addition, a history of AF
was a significant independent predictor of mortality in CRT
patients. Hayes et al1 showed in a retrospective study of
.36,000CRT patients that a reduction from 1% to 5% in ven-
tricular pacing was associated with increased mortality. Their
analysis also showed AF had an additive negative effect on
mortality. Themagnitude of the increase in%Vp in the current
study (7%) suggests that this algorithm could have a signifi-
cant clinical benefit in CRT patients with high AF burden.
Multivariate analysis suggests that the biggest impact of
the algorithm may be in patients with paroxysmal AF,
although the small number of subjects (n5 5) makes it diffi-
cult to extrapolate these results. However, this is a plausible
correlation, as a retrospective analysis of.12,000 CRT sub-
jects with AF demonstrated that those with paroxysmal AF
saw the greatest drop in %Vp during AF compared to those
with persistent or permanent AF.8 Because low %Vp during
AF was also a strong predictor of response in the multivariate
analysis, its correlation with paroxysmal AF provides an
explanation for why this group may see the largest effect.
Our data show that with the eCRTAF algorithm, 5 subjects
improved from ,90% to .90% eCRT, and an additional 5
subjects improved from ,95% to .95% eCRT. Moreover,
in the cohort receiving,80%Vp during control, the algorithm
improved %eCRT by a mean of 16%. The ability to deliver
more eCRT during AF may lead to better resynchronization
and consequently reduce HF symptoms. AV junctional abla-
tion (AVJA) is associatedwith improved outcomes in observa-
tional trials of patients with permanent AF who did not
experience clinical improvement and/or an adequate biventric-
ular pacing percentage with rate limiting drugs,9–13 but there
are no randomized controlled trials of AVJA for this
indication. The eCRTAF algorithm has the potential to
increase biventricular capture during AF without AVJA.
This could improve outcomes in patients not previously
known to have AF and avoid the need for AVJA in others
Plummer et al New Algorithm Increases CRT During AF 375by achieving high rates of biventricular capture. It may also
help to identify others for whom AVJA is the only
appropriate way to achieve sufficient biventricular capture.
When considering the applicability of this algorithm to the
general CRT patient population, it is important to keep in
mind that, although most CRT patients do not have AF at
initial implant, many will develop AF over the course of their
disease. A recent retrospective analysis by Hayes et al14 sug-
gests that as many as 30% of CRT patients will experience
clinically significant AF (1 day of atrial tachycardia/AF
for .6 hours) within 2 years of implant.
Because the eCRTAF algorithm involves additional pro-
cessing, the impact on device longevity may be a concern.
According to the manufacturer, a patient with permanent
AF (worse-case scenario) will experience a 2%–3% decrease
in device longevity. A 2.5-bpm increase in pacing rate will
have an additional 1%–2% impact on device longevity.
Study limitations
The majority of the subjects included in this study had perma-
nent or persistent AF. Given the small number of paroxysmal
AF subjects in the study, additional clinical data are needed to
confirm the preliminary findings about the algorithm behavior
in this group. In addition, the comparison of the new algo-
rithm to a control of no rate regularization algorithm at all
was only performed with a small acute dataset. The difference
in a chronic ambulatory setting remains to be determined.
It is possible that greater variation in RR intervals during AF
or an increased number of premature ventricular contractions
was associated with lower %VP, but this information was not
collected in this study. It also is possible that the algorithmwould
be more effective during regular tachycardias such as atrial
flutter, but this study was unable to evaluate this possibility.
Finally, this study did not evaluate long-term clinical
events, so additional investigation is needed to demonstrate
whether a higher %eCRT pacing would result in improved
clinical outcomes.Conclusion
In a cohort ofCRTsubjectswithhighAFburden, eCRTAFwas
shown to significantly increase%eCRTpacing duringAF from
80.8% to 87.8% (P,.001) and%Vp duringAF from83.2% to
90.0% (P,.001) while increasing mean HR by an average of
2.5 bpm (P ,.001). Given the significant proportion of CRT
patients who will develop AF over their disease course, this al-
gorithm could represent a noninvasive, low-risk strategy to in-
crease CRT delivery during AF, potentially improving CRT
response and preventing adverse outcomes.Acknowledgments
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